Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs

Nature ◽  
1991 ◽  
Vol 352 (6338) ◽  
pp. 815-818 ◽  
Author(s):  
Gyula Acsadi ◽  
George Dickson ◽  
Donald R. Love ◽  
Agnes Jani ◽  
Frank S. Walsh ◽  
...  
2016 ◽  
Vol 24 ◽  
pp. S226
Author(s):  
William-Édouard Gravel ◽  
Dominique L. Oulette ◽  
Chantale Maltais ◽  
Catherine Gérard ◽  
Hongmei L. Li ◽  
...  

2007 ◽  
Vol 18 (5) ◽  
pp. 1586-1594 ◽  
Author(s):  
Chang-Hao Cui ◽  
Taro Uyama ◽  
Kenji Miyado ◽  
Masanori Terai ◽  
Satoru Kyo ◽  
...  

Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder in children, is an X-linked recessive muscle disease characterized by the absence of dystrophin at the sarcolemma of muscle fibers. We examined a putative endometrial progenitor obtained from endometrial tissue samples to determine whether these cells repair muscular degeneration in a murine mdx model of DMD. Implanted cells conferred human dystrophin in degenerated muscle of immunodeficient mdx mice. We then examined menstrual blood–derived cells to determine whether primarily cultured nontransformed cells also repair dystrophied muscle. In vivo transfer of menstrual blood–derived cells into dystrophic muscles of immunodeficient mdx mice restored sarcolemmal expression of dystrophin. Labeling of implanted cells with enhanced green fluorescent protein and differential staining of human and murine nuclei suggest that human dystrophin expression is due to cell fusion between host myocytes and implanted cells. In vitro analysis revealed that endometrial progenitor cells and menstrual blood–derived cells can efficiently transdifferentiate into myoblasts/myocytes, fuse to C2C12 murine myoblasts by in vitro coculturing, and start to express dystrophin after fusion. These results demonstrate that the endometrial progenitor cells and menstrual blood–derived cells can transfer dystrophin into dystrophied myocytes through cell fusion and transdifferentiation in vitro and in vivo.


1992 ◽  
Vol 1 (1) ◽  
pp. 35-40 ◽  
Author(s):  
Dominic J.Wells ◽  
Kim E.Wells ◽  
Frank S.Walsh ◽  
Kay E.Davies ◽  
Geoffrey Goldspink ◽  
...  

Gene Therapy ◽  
2000 ◽  
Vol 7 (17) ◽  
pp. 1447-1457 ◽  
Author(s):  
S Braun ◽  
C Thioudellet ◽  
P Rodriguez ◽  
D Ali-Hadji ◽  
F Perraud ◽  
...  

2018 ◽  
Vol 10 (444) ◽  
pp. eaat0195 ◽  
Author(s):  
Xianjun Gao ◽  
Ning Ran ◽  
Xue Dong ◽  
Bingfeng Zuo ◽  
Rong Yang ◽  
...  

Exosomes are circulating nanovesicular carriers of macromolecules, increasingly used for diagnostics and therapeutics. The ability to load and target patient-derived exosomes without altering exosomal surfaces is key to unlocking their therapeutic potential. We demonstrate that a peptide (CP05) identified by phage display enables targeting, cargo loading, and capture of exosomes from diverse origins, including patient-derived exosomes, through binding to CD63—an exosomal surface protein. Systemic administration of exosomes loaded with CP05-modified, dystrophin splice–correcting phosphorodiamidate morpholino oligomer (EXOPMO) increased dystrophin protein 18-fold in quadriceps of dystrophin-deficient mdx mice compared to CP05-PMO. Loading CP05-muscle–targeting peptide on EXOPMO further increased dystrophin expression in muscle with functional improvement without any detectable toxicity. Our study demonstrates that an exosomal anchor peptide enables direct, effective functionalization and capture of exosomes, thus providing a tool for exosome engineering, probing gene function in vivo, and targeted therapeutic drug delivery.


2015 ◽  
Vol 20 (3) ◽  
Author(s):  
Rongqing Pang ◽  
Xiangqing Zhu ◽  
Jia Geng ◽  
Yongyun Zhang ◽  
Qiang Wang ◽  
...  

AbstractMultipotent stem cells have potential therapeutic roles in the treatment of Duchenne muscular dystrophy (DMD). However, the limited access to stem cell sources restricts their clinical application. To address this issue, we established a simple in vitro epigenetic reprogramming technique in which skin fibroblasts are induced to dedifferentiate into multipotent cells. In this study, human fibroblasts were isolated from circumcised adult foreskin and were reprogrammed by co-culture for 72 h with fish oocyte extract (FOE) in serum-free medium. The cells were then observed and analyzed by immunofluorescence staining, flow cytometry and in vitro differentiation assays. Then FOE-treated human fibroblasts were transplanted by tail vein injection into irradiated mdx mice, an animal model of DMD. Two months after injection, the therapeutic effects of FOE-treated fibroblasts on mdx skeletal muscle were evaluated by serum creatine kinase (CK) activity measurements and by immunostaining and RT-PCR of human dystrophin expression. The results indicated that the reprogrammed fibroblasts expressed higher levels of the pluripotent antigen markers SSEA-4, Nanog and Oct-4, and were able to differentiate in vitro into adipogenic cells, osteoblastic cells, and myotube-like cells. Tail vein injection of FOE-treated fibroblasts into irradiated mdx mice slightly reduced serum CK activity and the percentage of centrally nucleated myofibers two months after cell transplantation. Furthermore, we confirmed human dystrophin protein and mRNA expression in mdx mouse skeletal muscle. These data demonstrated that FOE-treated fibroblasts were multipotent and could integrate into mdx mouse myofibers through the vasculature.


2016 ◽  
Vol 24 (3) ◽  
pp. 564-569 ◽  
Author(s):  
Li Xu ◽  
Ki Ho Park ◽  
Lixia Zhao ◽  
Jing Xu ◽  
Mona El Refaey ◽  
...  

2006 ◽  
Vol 13 ◽  
pp. S16
Author(s):  
Bing Wang ◽  
Juan Li ◽  
Chunlian Chen ◽  
Xiancheng Jiang ◽  
Terry O'Day ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document